We recently teamed up with MS Microcaps to publish Company Spotlight reports on the companies presenting at its conference earlier this month. The reports aim to serve as an introduction to each company and provide a basic investment thesis. For access to full versions of all interviews please visit either mscliffnotes.substack.com or geoinvesting.com/free-trial/. Companies Mentioned: Marpai Inc. (MRAI:OTC) HireQuest Inc. (HQI:NASDAQ) QHSLab Inc. (USAQ:OTC) ACCESS Newswire Inc. (ACCS:NYSE) B...
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2022 OLDSMAR, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2022. Financial Results Revenue Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021. The revenues for fiscal 2022 consisted of $29.8 million in processing and storage fee revenue, $104,000 in product revenu...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2022 Financial Results OLDSMAR, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2022. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2022 were $7.7 million compared to $7.5 million for the third quarter of fiscal 2021. The revenues for the third quarter of fiscal 20...
Cord Blood Banking Leader Cryo-Cell Announces Special Cash Dividend OLDSMAR, Fla., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors declares a one-time, special cash dividend of $0.90 per share of common stock to be paid to its shareholders of record as of the close of business on September 2, 2022. Cryo-Cell’s Chairman of the Board and Co-CEO, David Portnoy, stated “Cryo-Cell’s Board of ...
Cord Blood Banking Leader Cryo-Cell Announces Transfer to the NYSE American Stock Exchange OLDSMAR, Fla., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (“Cryo-Cell”, the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that it will change its listing from the Nasdaq Capital Market to the NYSE American stock exchange on August 30, 2022. David Portnoy, Chairman and Co-CEO of Cryo-Cell, said, “The New York Stock Exchange has been trading stocks for over 225 years and is th...
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2022 Financial Results OLDSMAR, Fla., July 11, 2022 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2022. Financial Results Revenue Consolidated revenues for the second quarter of fiscal 2022 were $7.63 million compared to $7.21 million for the second quarter of fiscal 2021, a 6% increase. The revenues for the second qua...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.